AVB-620 is Avelas’ lead investigational product based on the science of activatable cell-penetrating peptides (ACPPs). AVB-620 has been designed to deliver a fluorescent marker specifically to cancer cells for real-time cancer detection.
AVB-620 is currently in a Phase II/III clinical trial for breast cancer margin detection during surgery. AVB-620 is administered by intravenous (IV) injection between ~3-20 hours prior to surgery. Beyond breast cancer, Avelas has plans to explore the use of AVB-620 during surgery for other types of cancer, including ovarian, colorectal, lung, head and neck, melanoma, and sarcoma.